| TECHNIQUES AND METHODS |
|
|
|
|
| Generation of Human β-thalassemia Induced Pluripotent Stem Cells Under Feeder-free and Xeno-free Conditions |
| FAN Yong, LUO Yu-mei, CHEN Xin-jie, SUN Xiao-fang |
| Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China |
|
|
|
Abstract β-thalassemia is an inherited blood disorder that is characterized by reduced synthesis of hemoglobin subunit beta. Even with transfusion and chelation therapy treatments, the life span of patients with thalassemia major (also called Cooley’s anemia) can only be extended for a limited time. The derivation of β-thalassemia patient specific induced pluripotent stem cells opens a new approach of treating β-thalassemia. For therapeutic usage of induced pluripotent stem (iPS) cells, to accomplish feeder-free and xeno-free culture is critical. However, most reprogramming protocols used to date involve the use of products of animal origin and mouse feeder cells. Here, human β-thalassemia iPS cells weve derived from commercially available xeno-free medium TeSRTM2 and StemAdhereTM Defined Matrix. A total of 5 feeder-free and xeno-free human β-thalassemia iPSC lines were generated, which could be continuously passaged in xeno-free conditions and maintained characteristics indistinguishable from hESCs, including colony morphology and growth behavior, expression of pluripotency-associated markers, and pluripotent differentiation ability in vitro and in teratoma assays.
|
|
Received: 14 December 2011
Published: 25 June 2012
|
|
|
|
|
[1] Takahashi K, Tanabe K, Ohnuki M, et.al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007,131: 861-872.
[2] Ye L, Chang J C, Lin C,et.al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A, 2009,106: 9826-9830.
[3] Wang Y, Jiang Y, Liu S,et al. Generation of induced pluripotent stem cells from human beta-thalassemia fibroblast cells. Cell Res, 2009,19: 1120-1123.
[4] Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science, 2007, 318: 1920-1923.
[5] Martin M J, Muotri A, Gage F,et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med, 2005, 11: 228-232.
[6] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature, 2007, 448: 313-317.
[7] Li Y, Zhang Q, Yin X,et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res, 2011,21: 196-204.
[8] Yuan X, Wan H, Zhao X, et al. Brief report: combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells, 2011,29: 549-553.
[9] Zhou H, Wu S, Joo J Y, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 2009, 4: 381-384.
[10] Kim D, Kim C H, Moon J I, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 2009, 4: 472-476.
[11] Warren L, Manos P D, Ahfeldt T,et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 2011, 7: 618-630. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
